PMID- 34760967 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221021 IS - 2304-3881 (Print) IS - 2304-389X (Electronic) IS - 2304-3881 (Linking) VI - 10 IP - 5 DP - 2021 Oct TI - Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice. PG - 631-645 LID - 10.21037/hbsn.2020.03.14 [doi] AB - BACKGROUND: To compare the treatment effectiveness and safety among transarterial infusion chemotherapy (TAI) with FOLFOX regimen, transarterial chemoembolization (TACE), and sorafenib in patients with BCLC stage C hepatocellular carcinoma (HCC). METHODS: The data of consecutive patients with BCLC stage C HCC treated with TAI, TACE, or sorafenib from January 2015 to December 2018 at three centers were retrospectively analyzed. Propensity-score matched (PSM) analysis was pairwise performed to reduce selection bias. Treatment effectiveness and safety were evaluated and compared using the Kaplan-Meier method, log-rank test, Cox regression models, and chi(2) test. RESULTS: The median overall survival (OS) in the matched TAI cohort was significantly longer than the sorafenib cohort (19.6 vs. 7.5 months, P=0.009), and the TACE cohort (estimated 27.8 vs. 6.6 months, P<0.001). The difference in median progression-free survival (PFS) between the matched TAI and sorafenib cohorts was not significant (5.8 vs. 2.3 months, P=0.219). The median PFS in the matched TAI cohort was significantly longer than the TACE cohort (6.5 vs. 2.8 months, P<0.001). The objective response rate (ORR) in the matched TAI cohort was significantly higher than the sorafenib cohort (36.4% vs. 0.0%, P<0.001) and the TACE cohort (48.7% vs. 4.7%, P<0.001). The incidences of adverse events (AEs) were similar among these three cohorts. CONCLUSIONS: TAI with FOLFOX regimen was an effective and safe therapy that improved survival of patients with BCLC stage C HCC. CI - 2021 Hepatobiliary Surgery and Nutrition. All rights reserved. FAU - Li, Shaohua AU - Li S AD - Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. FAU - Mei, Jie AU - Mei J AD - Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. FAU - Wang, Qiaoxuan AU - Wang Q AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Shi, Feng AU - Shi F AD - Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. FAU - Liu, Hongyan AU - Liu H AD - State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Zhao, Ming AU - Zhao M AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. AD - Department of Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Lu, Lianghe AU - Lu L AD - Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. FAU - Ling, Yihong AU - Ling Y AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. AD - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Guo, Zhixing AU - Guo Z AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. AD - Department of Ultrasound, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Guo, Yabing AU - Guo Y AD - State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Chen, Xiaoming AU - Chen X AD - Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. FAU - Shi, Ming AU - Shi M AD - Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. FAU - Lau, Wan Yee AU - Lau WY AD - Faculty of Medicine, the Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China. FAU - Wei, Wei AU - Wei W AD - Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. FAU - Guo, Rongping AU - Guo R AD - Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. LA - eng PT - Journal Article PL - China (Republic : 1949- ) TA - Hepatobiliary Surg Nutr JT - Hepatobiliary surgery and nutrition JID - 101600750 CIN - Hepatobiliary Surg Nutr. 2022 Oct;11(5):775-778. PMID: 36268255 PMC - PMC8527433 OTO - NOTNLM OT - FOLFOX OT - Hepatocellular carcinoma (HCC) OT - sorafenib OT - transarterial chemoembolization OT - transarterial infusion chemotherapy COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/hbsn.2020.03.14). Dr. WYL serves as the unpaid editorial board members of Hepatobiliary Surgery and Nutrition. The other authors have no conflicts of interest to declare. EDAT- 2021/11/12 06:00 MHDA- 2021/11/12 06:01 PMCR- 2021/10/01 CRDT- 2021/11/11 07:01 PHST- 2019/12/16 00:00 [received] PHST- 2020/02/24 00:00 [accepted] PHST- 2021/11/11 07:01 [entrez] PHST- 2021/11/12 06:00 [pubmed] PHST- 2021/11/12 06:01 [medline] PHST- 2021/10/01 00:00 [pmc-release] AID - hbsn-10-05-631 [pii] AID - 10.21037/hbsn.2020.03.14 [doi] PST - ppublish SO - Hepatobiliary Surg Nutr. 2021 Oct;10(5):631-645. doi: 10.21037/hbsn.2020.03.14.